Pulmatrix, Inc. reported its financial results for the third quarter of 2025, revealing a significant decline in revenue and a continued net loss. The company did not generate any revenue during the three and nine months ended September 30, 2025, compared to $366,000 and $7.8 million for the same periods in 2024, respectively. This decrease is attributed to the completion of the wind-down of the PUR1900 Phase 2b clinical trial, which was a primary source of revenue in the previous fiscal year. The net loss for the third quarter was $877,000, a reduction from a loss of $2.6 million in the same quarter of 2024. For the nine-month period, the net loss was $4.2 million, down from $7.6 million in 2024.
Operating expenses for Pulmatrix also saw a notable decline, totaling $866,000 for the third quarter of 2025, compared to $3 million in the same quarter of 2024. This reduction was primarily driven by lower research and development costs, which fell to $8,814 from $41,000 year-over-year, and a decrease in general and administrative expenses from $2.2 million to $858,000. The overall decrease in operating expenses reflects the company's strategic shift following the MannKind transaction, which resulted in a significant reduction in personnel and operational costs.
In terms of strategic developments, Pulmatrix is currently focused on a merger with Cullgen Inc., which was approved by its stockholders in June 2025. The merger is expected to enhance Pulmatrix's capabilities and market position, although it remains contingent on regulatory approvals, including from the China Security Regulatory Commission. The company has extended the deadline for the merger's completion to October 12, 2025, as it awaits necessary approvals. If successful, the merger will allow Pulmatrix to leverage Cullgen's assets while continuing to explore monetization opportunities for its proprietary iSPERSE™ technology and clinical assets.
As of September 30, 2025, Pulmatrix reported total assets of $4.98 million, a decrease from $9.94 million at the end of 2024. The company's cash and cash equivalents stood at $4.79 million, down from $9.52 million at the end of the previous fiscal year. The company anticipates that its existing cash will be sufficient to fund operations for at least the next 12 months, but it will require additional funding to continue the development of its product candidates. The management has indicated that future operations are highly dependent on the successful completion of the merger and the ability to secure further financing.
Looking ahead, Pulmatrix's management has expressed cautious optimism regarding the potential for its product candidates, including PUR3100 for acute migraine treatment and PUR1800 for chronic obstructive pulmonary disease. However, the company acknowledges the inherent risks and uncertainties associated with product development, regulatory approvals, and market conditions. The successful advancement of these candidates will require significant additional funding and resources, and the company is actively seeking partnerships and collaborations to support its strategic objectives.
About Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company specializing in inhaled therapies using its proprietary iSPERSE dry powder platform. It develops treatments for respiratory diseases and CNS disorders, including migraine, COPD, and ABPA. The company focuses on innovative drug delivery, aiming to improve efficacy and safety, and seeks strategic partnerships and monetization of its clinical assets in the global respiratory and neurological markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.